A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145) in Patients with Solid Tumors
Sponsor: |
Iovance Biotherapeutics, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS5355 |
U.S. Govt. ID: |
NCT03645928 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this clinical research study is to find out if an Investigational Drug, called LN-144/LN-145, is safe and beneficial in the treatment of participants with Metastatic Melanoma, or head and neck squamous cell carcinoma (HNSCC) when given in combination with a medication, named pembrolizumab (Keytruda), or in participants with non-small cell lung cancer (NSCLC), when LN-144/LN-145 is given alone as a single therapy. The LN-144/LN-145 Study drug is made up of specialized white blood cells called lymphocytes or T cells that are derived from your tumor after a small piece is obtained by surgical removal. This piece of your own tumor is sent to a centralized manufacturing facility where T cells that have infiltrated your tumor are isolated and grown to create the study drug LN-144/LN-145, which are infused back into your body.
This study is closed
Investigator
Richard Carvajal, MD
Do you have a melanoma, head and neck squamous cell carinoma (HNSCC), or non-small cell lung cancer (NSCLC)? |
Yes |
No |
Does your cancer continue to grow or cannot be removed by surgery? |
Yes |
No |
Are you 18 years of age or older and younger than 70 years of age? |
Yes |
No |